Oncolytic viral therapies (Q35852258)

10 August 2017

1 reference

title

Oncolytic viral therapies (English)

1 reference

10 August 2017

1 reference

Eugene Lin

1

1 reference

PubMed ID

15286681

10 August 2017

John Nemunaitis

series ordinal

2

1 reference

10 August 2017

1 October 2004

1 reference

10 August 2017

1 reference

10 August 2017

11

1 reference

10 August 2017

10

1 reference

10 August 2017

643-664

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700733

10 August 2017

0 references

cites work

Getting oncolytic virus therapies off the ground

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Regression of Burkitt's lymphoma in association with measles infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Present status of oncolytic virus studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Treatment of human cancer with mumps virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Studies on the use of viruses in the treatment of carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Replicating vectors for gene therapy of cancer: risks, limitations and prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

p53 and DNA polymerase alpha compete for binding to SV40 T antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

p53-dependent cell death/apoptosis is required for a productive adenovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Receptors mediating adenovirus attachment and internalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

The role of the nuclear pore complex in adenovirus DNA entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Specific binding of the adenovirus capsid to the nuclear envelope

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Dynein- and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Nuclear import of adenovirus DNA in vitro involves the nuclear protein import pathway and hsc70.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Immune evasion by adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Viral transactivating proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

The adenovirus type 5 E1B-55K oncoprotein is a highly active shuttle protein and shuttling is independent of E4orf6, p53 and Mdm2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Adenovirus proteins that subvert host defenses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Induction of cell death by adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Viral mechanisms of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

One step ahead of the game: viral immunomodulatory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

CrmE, a novel soluble tumor necrosis factor receptor encoded by poxviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Selectively replicating viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Effects of liposome-encapsulated dichloromethylene diphosphonate on macrophage function and endotoxin-induced mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

The liposome-mediated macrophage 'suicide' technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Cell cycle control and cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Promising new agents in the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Targeted gene delivery by tropism-modified adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Targeting of adenoviral vectors through a bispecific single-chain antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Use of a novel cross-linking method to modify adenovirus tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Blood clearance rates of adenovirus type 5 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

An oncolytic measles virus engineered to enter cells through the CD20 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Efficiency of measles virus entry and dissemination through different receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Targeting of adenoviral vectors for gene therapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Novel gene therapy approach for nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Tissue-specific transcriptional targeting of a replication-competent retroviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Combined transductional and transcriptional targeting of melanoma cells by artificial virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Tumor-specific transcriptional targeting of suicide gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Intergeneric poliovirus recombinants for the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Glucocorticoids regulate expression of dihydrofolate reductase cDNA in mouse mammary tumour virus chimaeric plasmids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Tumor-specific expression of anti-mdr1 ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Vargula hilgendorfii luciferase: a secreted reporter enzyme for monitoring gene expression in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

New developments in the virus therapy of cancer: a historical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Oncolytic herpes simplex virus vectors for cancer virotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Act locally, think globally.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Tumor-specific intravenous gene delivery using oncolytic adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Remission of chronic lymphocytic leukemia after smallpox vaccination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Regression of Hodgkin's disease after measles

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Multiple myeloma: report of a case showing unusual remission lasting two years following severe hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Note on the experimental use of rabies vaccine for melanomatosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

ONYX-015: clinical data are encouraging

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Viruses as oncolytic agents: a new age for "therapeutic" viruses?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Advances in adenoviral vectors: from genetic engineering to their biology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Immunomodulation by viruses: the myxoma virus story

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Vaccinia virus immune evasion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Selective Depletion of Liver and Splenic Macrophages Using Liposomes Encapsulating the Drug Dichloromethylene Diphosphonate: Effects on Antimicrobial Resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Kupffer cell elimination enhances development of liver schizonts of Plasmodium berghei in rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Molecular cloning and deletion of the gene encoding aspergillopepsin A from Aspergillus awamori

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Will a twist of viral fate lead to a new cancer treatment?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Transcriptional targeting of herpes simplex virus for cell-specific replication

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700733

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700733

1 reference

10 August 2017

1 reference

PubMed ID

15286681